Latest Articles
Jes Burns and Brook Herbert win national award for reporting on cancer research - Oregon Public Broadcasting - OPB
Jes Burns and Brook Herbert win national award for reporting on cancer research Oregon Public Broadcasting - OPB
Published: April 13, 2026, 11:38 p.m.
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace
Published: April 13, 2026, 5:57 p.m.
Endometriosis: ‘I was vomiting green. It’s like cancer without being cancer.’ - Luxembourg Times
Endometriosis: ‘I was vomiting green. It’s like cancer without being cancer.’ Luxembourg Times
Published: April 13, 2026, 4 p.m.
Near-Perfect Disease Control for Bispecific in Advanced Endometrial Cancer - MedPage Today
Near-Perfect Disease Control for Bispecific in Advanced Endometrial Cancer MedPage Today
Published: April 13, 2026, 3:43 p.m.
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks
Published: April 13, 2026, 12:29 p.m.
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
Biontech prepares FDA application after strong phase II results in endometrial cancer medwatch.com
Published: April 13, 2026, 12:14 p.m.
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal - Stock Titan
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal Stock Titan
Published: April 13, 2026, 11:55 a.m.
'Non-invasive' womb cancer test could be rolled out - BBC
'Non-invasive' womb cancer test could be rolled out BBC
Published: April 13, 2026, 11:42 a.m.
GSK ovarian and womb cancer drug shows promise in early trial - FemTech World
GSK ovarian and womb cancer drug shows promise in early trial FemTech World
Published: April 13, 2026, 11:05 a.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - Sahm
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data Sahm
Published: April 13, 2026, 10:35 a.m.
Link copied to clipboard!